NCT02162888 - A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate

Interventions

DRUG

Test Product (Bendamustine)

Trial Locations (10)

Oncology Institute of Hope and Innovation, Long Beach

Cancer Center of Kansas, Wichita

Regional Cancer Care Associates, Cherry Hill

Penn State University Hershey Medical Center, Hershey

Greenville Hospital System University Medical Center, Greenville

Texas Oncology, Fort Worth

Scott & White Healthcare, Temple

Virginia Oncology Associates, Norfolk

Evergreen Hematology & Oncology, Spokane

Yakima Valley Memorial Hospital/North Star Lodge, Yakima